Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth
- 29 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 343, 303-313
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA157738, CA198999)
- Sveriges Kommuner och Landsting
- Eshelman Innovation
This publication has 52 references indexed in Scilit:
- Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritisArthritis Research & Therapy, 2012
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory CellsCancer Research, 2011
- T cells and follicular dendritic cells in germinal center B‐cell formation and selectionImmunological Reviews, 2010
- Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patientsBritish Journal of Cancer, 2008
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory ResponsesImmunity, 2008
- Identification of stem cells in small intestine and colon by marker gene Lgr5Nature, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granulomaBlood, 2006
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996